7*24 Hotline：
Huabei Pharmaceutical Co., Ltd. (600812)
Huabei Pharmaceutical Group Co., Ltd. (hereinafter referred to as: Huayao group) is located in Shijiazhuang, the capital of Hebei Province. The predecessor of Huabei pharmaceutical factory is a key construction project during the first five year plan period in China. It began to prepare for construction in June 1953, and was completed and put into operation in June 1958. It created a history of large-scale production of antibiotics in China, and made important contributions to the cause of human health, the development of national pharmaceutical industry and the change of the situation of lack of medicine in China. In 1992, Huabei Pharmaceutical Co., Ltd. was reorganized and established. In 1994, it was listed on the Shanghai Stock Exchange (Stock Name: Huabei pharmaceutical 600812). In January 1996, Huabei pharmaceutical factory was officially transformed into a wholly state-owned company, Huabei Pharmaceutical Group Co., Ltd. In June 2009, with the approval of Hebei provincial government, Jizhong energy group implemented the reorganization of Huayao group.
Over the years, adhering to the enterprise tenet of "human health first, quality first forever", Huayao group has been continuously innovating, steadily operating, gradually expanding, expanding its business scope, maintaining excellent development performance, and its main economic and technical indicators have always been in the forefront of the same industry in China. By the end of 2018, Huayao group had total assets of 20.6 billion yuan, nearly 15000 employees, more than 40 subsidiaries (branches), and three national innovation platforms, including the National Engineering Research Center for microbial drugs, the State Key Laboratory for antibody drug development, and the national local joint engineering laboratory for antibiotic enzyme catalysis and crystallization technology There are nearly 1000 product specifications in the fields of modern biotechnological drugs, vitamins and health care products, modern traditional Chinese medicine, biological agriculture and veterinary drugs, and the treatment fields cover anti infection, cardio cerebrovascular, nephropathy, anti-tumor and immune regulation. The process routes and production layout of the main production units are all designed and implemented in accordance with the current version of GMP in Europe and the United States and the new version of GMP in China, It has a modern pharmaceutical production platform with international leading level.
In 2018, Huayao group achieved an operating revenue of 13.2 billion yuan and a profit and tax of 910 million yuan. At present, China Pharmaceutical Group insists on guiding Xi Jinping's new socialist concept with Chinese characteristics, fully implementing the new development concept, establishing market-oriented, capitalized and internationalized strategic orientation, taking innovation, capital and talent as the driving force, and taking strategic reengineering, management reengineering, cultural reconstruction and Party building innovation as the starting point to consolidate the development of chemical pharmaceutical preparations industry. Focus on the development of biopharmaceutical industry, cultivate and develop the health consumer goods and agricultural and veterinary medicine industry, actively build the API industry chain with competitive advantages, promote the promotion of product value, brand value and enterprise value, strive to change year by year, make great changes in three years and reshape a Xinhua Pharmaceutical in five years, and strive to build a domestic leading international first-class modern pharmaceutical and health industry group.
oil wellhead